Vincent O. Mallet

Vincent O. Mallet appears in the volume as a Paris-based hepatology researcher whose work helps define hepatitis C as more than a liver infection. He is listed among the authors of “Hepatitis C: Epidemiology, Diagnosis, Natural History and Therapy,” alongside Stanislas Pol, Anaïs Vallet-Pichard, and Marion Corouge, and is affiliated with Université Paris Descartes, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin, the hepatology unit, INSERM U-1016, and Institut Cochin. His contribution belongs to the book’s central movement from population-level burden and diagnostic classification toward treatment, fibrosis, extrahepatic disease, and the changing technical language of viral medicine.

Identity and Scholarly Setting

Vincent O. Mallet is presented through institutional and collaborative affiliations rather than biography. His professional setting is Paris, specifically the hepatology service at Hôpital Cochin and the research structures associated with Université Paris Descartes and INSERM. The placement is significant: the chapter is not an isolated clinical note but part of an organized research program joining hepatology, virology, pathology, and therapeutic evaluation.

His name also appears as the author of a study on the relationship between regression of cirrhosis and outcome in chronic hepatitis C. That work gives a concrete dimension to the volume’s account of treatment. The goal of antiviral therapy is not merely to suppress a laboratory signal; in selected circumstances, sustained virologic response is described as complete recovery of infection, accompanied by fibrosis remodeling when liver comorbidities are absent. Mallet’s scholarly presence therefore links virologic response to structural change in the liver and, ultimately, to patient outcome.

The Disease Framework He Helps Establish

The chapter associated with Mallet describes hepatitis C virus infection as a major global public-health burden, with an estimated prevalence of 3 percent and approximately 170 million infected people worldwide. Although new infections were declining in industrialized countries, morbidity, mortality, and the associated costs were expected to rise, with models projecting continued increases in hepatocellular carcinoma and hepatitis C-related mortality until about 2015. This epidemiological framing makes the disease a long-term population problem rather than a collection of isolated clinical cases.

The chapter also insists that hepatitis C is systemic. Its consequences extend beyond the liver to autoimmune, dermatological, and renal disease, including cryoglobulinemia-associated vasculitis and membranoproliferative glomerulonephritis. That breadth resonates with the volume’s nephrology focus, where hepatitis C is treated as both an important cause and a consequence of chronic kidney disease. Mallet’s contribution thus participates in a reframing of the infected patient: liver injury remains central, but it must be assessed alongside extrahepatic manifestations and the complications that arise in dialysis and transplantation.

Diagnostic and Therapeutic Reasoning

The diagnostic scheme presented in the chapter is deliberately layered. Screening begins with anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assays, but antibody positivity alone cannot distinguish resolved infection from ongoing disease. Active chronic infection requires both anti-HCV positivity and detectable HCV RNA, with molecular assays capable of detecting levels around 15 IU/ml. This distinction prevents a historical exposure from being treated as equivalent to current viral replication.

Once active chronic infection has been established, the assessment must cover both hepatic and extrahepatic impact. Liver injury can be evaluated by biopsy or by noninvasive methods, including biochemical scores and FibroScan measurement of liver stiffness. These methods may avoid roughly half of liver biopsies and permit yearly fibrosis follow-up in untreated patients. The same diagnostic logic extends to cryoglobulinemia-associated vasculitis, whose renal, cutaneous, and neurological manifestations may be clinically decisive even when liver enzyme abnormalities are normal or only mild.

The therapeutic framework remains anchored in pegylated interferon and ribavirin, with treatment decisions shaped by viral kinetics, genotype, fibrosis, symptoms, and extrahepatic disease. At the acute stage, persistent HCV RNA after approximately 12 weeks indicates a 24-week course of pegylated interferon; detectable RNA at week 4 or week 12 can justify extending therapy to 48 weeks. In chronic infection, treatment may be considered at any stage, particularly when chronic fatigue, necroinflammation, fibrosis beyond Metavir stage 1, or symptomatic cryoglobulinemia-associated vasculitis is present.

Mallet’s research context also belongs to the transition toward direct-acting antivirals. The volume identifies viral enzymes as therapeutic targets and describes protease and polymerase inhibitors, broader-spectrum NS5A or entry inhibitors, new interferons, and cyclophilin inhibitors. First-generation telaprevir- and boceprevir-based triple therapy increased sustained virologic response rates in genotype 1 infection by approximately 20 to 30 percent. About 75 percent of previously untreated genotype 1 patients achieved sustained virologic response with telaprevir-based treatment, while boceprevir-based treatment achieved approximately 65 percent; among treatment-experienced patients, response varied sharply between previous relapsers, partial responders, and null responders. The promise of these drugs was accompanied by practical limits, including rash, anemia, cost, adherence, viral resistance, and drug interactions.

Renal and Transplantation Significance

The systemic perspective associated with Mallet’s work is especially important for renal medicine. Hepatitis C is the major cause of mixed cryoglobulinemia, a vasculitis that can produce purpura, arthralgias, Raynaud phenomena, neuropathy, hypocomplementemia, and kidney disease. Renal presentations range from proteinuria and hematuria to nephritic or nephrotic syndrome, while clinical signs such as purpura or neuropathy may precede kidney disease by several years. Type II mixed cryoglobulinemia and type I membranoproliferative glomerulonephritis are especially characteristic associations.

The volume extends this concern into kidney transplantation. Active infection must be distinguished carefully in candidates for transplantation, because as many as 25 percent of patients with active infection may already have advanced fibrosis despite compensated liver disease. After transplantation, hepatitis C is associated with poorer long-term survival, increased liver-related mortality, proteinuria, immune complex-mediated glomerulonephritis, and renal allograft loss. De novo membranoproliferative glomerulonephritis may be accompanied by type II mixed cryoglobulinemia, while pathological examination may need electron microscopy to distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy.

At the same time, the evidence does not support leaving infected patients indefinitely on dialysis when transplantation is otherwise appropriate. Studies summarized in the volume found lower mortality among HCV-infected patients who received kidney transplants than among those who remained on dialysis or on the waiting list, provided advanced liver injury was excluded before transplantation. This contrast captures the clinical balance Mallet’s work helps illuminate: hepatitis C increases risk, but risk assessment and treatment can transform that risk into a basis for informed intervention rather than automatic exclusion.

Narrative and Scientific Role

Mallet’s role in the volume is therefore collaborative and connective. His named authorship places him within a Paris hepatology network, while his research on cirrhosis regression supplies an outcome-oriented counterpoint to the chapter’s epidemiology and diagnostic algorithms. The resulting portrait is not of a character developed through personal scenes, but of a medical investigator whose significance emerges through the knowledge architecture of the book.

That architecture moves from prevalence to proof, from antibody to RNA, from viral genotype to targeted drug, and from liver fibrosis to renal and transplant consequences. Mallet’s contribution helps stabilize the distinctions on which clinical action depends: past exposure is not active infection, viral suppression is not merely a numerical change, and liver disease cannot be separated from the systemic and renal life of hepatitis C. His scholarly presence reinforces the volume’s larger claim that progress in hepatitis C medicine comes from joining surveillance, molecular testing, pathology, therapy, and long-term outcome rather than treating any one of them as sufficient alone.